A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Public ClinicalTrials.gov record NCT02497287. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).
Study identification
- NCT ID
- NCT02497287
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 802 participants
Conditions and interventions
Conditions
Interventions
- Esketamine (Intranasal Spray) Drug
- Duloxetine (Oral Antidepressant) Drug
- Escitalopram (Oral Antidepressant) Drug
- Sertraline (Oral Antidepressant) Drug
- Venlafaxine Extended Release (XR) (Oral Antidepressant) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2015 (Actual)
- Primary completion
- Oct 28, 2017 (Actual)
- Completion
- Oct 28, 2017 (Actual)
- Last update posted
- Apr 29, 2025
2015 – 2017
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Marietta | Georgia | — | — |
| Not listed | Iowa City | Iowa | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Watertown | Massachusetts | — | — |
| Not listed | Cedarhurst | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Staten Island | New York | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Allentown | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Wichita Falls | Texas | — | — |
| Not listed | Richland | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02497287, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2025 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02497287 live on ClinicalTrials.gov.